Do weight loss tablets work as well as injections?

Are the weight loss results from tablets comparable to what injections produce?

Not quite, not yet. The injection-based GLP-1 medicines have a head start of several years in the evidence base, and the trial numbers still reflect that. In the SURMOUNT-1 study, tirzepatide (sold in the UK as Mounjaro) produced an average weight reduction of around 20–21% at the highest licensed dose over 72 weeks, in adults with obesity and no diabetes. The Wegovy injection trial (STEP 1, 68 weeks) recorded approximately 15% average reduction at the 2.4mg weekly maintenance dose. Those are substantial, well-replicated findings.

The Wegovy tablet (oral semaglutide, approved by the MHRA in June 2026) comes in at roughly 13.6% average weight loss over 64 weeks in the OASIS 4 phase 3 trial, rising to about 17% among participants who were fully adherent throughout. That adherence caveat matters: if you keep to the tablet's morning routine consistently, the gap narrows considerably, particularly when you compare it with the 2.4mg injection. The new 7.2mg Wegovy injection dose, approved in April 2026, is reported to narrow the gap with tirzepatide further still, with around 20.7% average loss over 72 weeks.

So the tablet is genuinely effective, but the current data places it a step behind the highest-performing injections for average weight reduction. If you want to dig into how these two approaches stack up in more detail, you can explore whether weight loss tablets are as good as injections before deciding which route suits you. You can read more about the licensed GLP-1 weight loss injections available in the UK to see the full picture alongside these tablet figures.

Does the way you take a medicine affect how well it works?

Yes, and in more than one way. Oral semaglutide relies on a specific absorption window in the stomach, which is why the Wegovy tablet has strict instructions: first thing in the morning, on an empty stomach, swallowed whole with a small amount of plain water, and nothing else (no coffee, no food, no other tablets) for at least 30 minutes afterwards. Miss that window consistently and bioavailability drops, which is part of why the adherent-participant figure in OASIS 4 (around 17%) is notably higher than the overall average (around 13.6%). The full Wegovy tablet details are on our treatment page, including the dosing schedule a prescriber would follow.

Injections bypass the gut entirely, sitting just under the skin and releasing the medicine directly into subcutaneous tissue. That route is more predictable in terms of absorption. It also means injections are unaffected by meals, other medications taken at the same time, or gastrointestinal conditions that could reduce tablet uptake. A quick practical check: if you are already taking any medication first thing in the morning (a thyroid tablet, for example) that timing conflict is worth raising with a prescriber before choosing the oral route.

On the other side of the ledger: no refrigeration is needed for the tablet, it travels well, and for people who are genuinely uncomfortable with self-injecting, having a once-daily tablet option removes a real barrier. Comfort with the administration route is not a trivial factor, it feeds directly into adherence, and adherence feeds directly into outcomes.

Who might suit a tablet, and who might do better with an injection?

Neither route automatically suits everyone, and the licensed eligibility criteria differ slightly. Both the Wegovy tablet and the Wegovy injection require a BMI of 30 or above, or 27 or above with at least one weight-related health condition such as high blood pressure or type 2 diabetes. Mounjaro (tirzepatide injection) has the same general threshold. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The choice between tablet and injection, though, goes beyond BMI numbers.

The tablet-versus-injection decision often comes down to a few practical and medical questions. Do you have any condition affecting how your stomach or small intestine absorbs medicines? Do you have a morning routine you can reliably protect for 30 minutes? Are you on other medicines that need to be taken first thing? How do you feel about weekly injections? Prescribers at services like ours work through exactly these questions, they are not abstract considerations but real factors that affect which medicine is likely to work best for a given person. You can find out more about how the different treatment options compare on our weight loss treatment overview.

Side effects also inform the choice. Both the tablet and injections share a broadly similar gastrointestinal profile: nausea, constipation, loose stools, and indigestion are the most commonly reported, usually most pronounced when starting or moving up a dose and then settling as the body adjusts. The OASIS 4 trial found 74% of oral semaglutide participants reported gastrointestinal effects versus 42% on placebo, that is higher than in comparable injection trials, though most were mild to moderate. The NHS medicines page for semaglutide lists the full side-effect profile worth reading before starting either form. For urgent symptoms (severe abdominal pain that reaches through to the back) seek medical attention promptly; the MHRA has highlighted acute pancreatitis as a rare but serious risk with GLP-1 medicines.

Are weight loss tablets available on the NHS, and does that affect which route people choose?

Currently, the Wegovy tablet is not available on the NHS. It received MHRA approval in June 2026 but would require a separate NICE appraisal before NHS commissioning, a process that takes time. The Wegovy injection has NICE approval (TA875) but access through specialist NHS services involves waiting lists that are commonly long. Mounjaro (tirzepatide) received NICE approval in December 2024 (TA1026) and is being rolled out via NHS primary care in phases, though GP participation is optional and not yet universal.

For many people, the practical upshot is that private prescription is the only accessible route in the near term, for both tablets and injections. A regulated online pharmacy can offer same-day clinical review, and the real cost of private GLP-1 treatment is worth understanding clearly before comparing options. What you are paying for (legitimate supply chain, clinical oversight, aftercare) matters as much as the headline figure. If you are specifically considering semaglutide in injectable form, our oz weight loss injection page covers how that option works and what to expect from the process.

If you are weighing up both routes, speaking to a prescriber is the most efficient path. They can review your health history, any medicines you are currently taking, and your preferences, then recommend which licensed treatment is the better clinical fit. That conversation is free at nume, with no obligation to proceed. Speak to our prescribers if you would like that assessment.